DXR · Insider Trading
Daxor Corporation Common Stock
Every open-market purchase and sale reported by DXR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-01 | John Jefferies | Chief Medical Officer | A | +2,451 | — |
| 2026-06-25 | Edward Feuer | Director | A | +2,500 deriv. | — |
| 2026-06-25 | Michael Richard Feldschuh | Chief Executive Officer | A | +30,000 | — |
| 2026-06-25 | Henry D. Cremisi | Director | A | +2,500 deriv. | — |
| 2026-06-25 | Jonathan Adam Feldschuh | Chief Scientific Officer | A | +25,000 | — |
| 2026-06-25 | Joy S. Goudie | Director | A | +2,500 deriv. | — |
| 2026-06-25 | Caleb DesRosiers | Director | A | +2,500 deriv. | — |
| 2026-06-25 | Robert J Michel | Chief Financial Officer | A | +12,000 | — |
| 2026-04-10 | Michael Richard Feldschuh | Chief Executive Officer | Buy | +1,000 | +$9.07K |
| 2026-03-24 | John Jefferies | Chief Medical Officer | Buy | +5,941 | — |
| 2025-12-11 | Jonathan Adam Feldschuh | Chief Scientific Officer | Buy | +18,000 | — |
| 2025-12-11 | Robert J Michel | Chief Financial Officer | Buy | +3,000 | — |
| 2025-11-14 | John Jefferies | Chief Medical Officer | Buy | +2,344 | — |
| 2025-06-26 | Caleb DesRosiers | Director | A | +2,500 deriv. | — |
| 2025-06-26 | Joy S. Goudie | Director | A | +2,500 deriv. | — |
| 2025-06-26 | Edward Feuer | Director | A | +2,500 deriv. | — |
| 2025-06-26 | Henry D. Cremisi | Director | A | +2,500 deriv. | — |
| 2025-04-07 | Michael Richard Feldschuh | Chief Executive Officer | Buy | +2,063 | +$16.28K |
| 2025-03-27 | Michael Richard Feldschuh | Chief Executive Office | Buy | +1,000 | +$8.13K |
| 2025-03-20 | Michael Richard Feldschuh | Chief Executive Officer | Buy | +1,492 | +$11.52K |
| 2025-03-20 | Michael Richard Feldschuh | Chief Executive Officer | Buy | +647 | +$5.27K |
| 2025-03-11 | Robert J Michel | Chief Financial Officer | Buy | +1,000 | +$8.00K |
| 2025-03-11 | Michael Richard Feldschuh | Chief Executive Officer | Buy | +3,360 | +$25.80K |
| 2024-12-10 | Jonathan Adam Feldschuh | Chief Scientific Officer | Buy | +32,000 | — |
| 2024-12-10 | Michael Richard Feldschuh | Chief Executive Officer | Buy | +45,000 | — |
| 2024-12-10 | Robert J Michel | Chief Financial Officer | Buy | +4,750 | — |
| 2024-07-17 | Edward Feuer | Director | A | +2,500 deriv. | — |
| 2024-07-17 | Caleb DesRosiers | Director | A | +2,500 deriv. | — |
| 2024-07-17 | Henry D. Cremisi | Director | A | +2,500 deriv. | — |
| 2024-07-17 | Joy S. Goudie | Director | A | +2,500 deriv. | — |
| 2024-03-27 | Robert J Michel | Chief Financial Officer | Buy | +750 | +$6.52K |
| 2024-03-06 | Edward Feuer | Director | Buy | +1,000 | +$7.21K |
| 2023-12-06 | Robert J Michel | Chief Financial Officer | Buy | +120 | +$930 |
| 2023-12-01 | Robert J Michel | Chief Financial Officer | Buy | +180 | +$1.40K |
| 2023-12-01 | Michael Richard Feldschuh | Chief Executive Officer | Buy | +800 | +$6.24K |
| 2023-11-27 | Robert J Michel | Chief Financial Officer | Buy | +500 | +$3.97K |
| 2023-11-24 | Michael Richard Feldschuh | CHIEF EXECUTIVE OFFICER | A | +84 | +$643 |
| 2023-11-13 | Michael Richard Feldschuh | CHIEF EXECUTIVE OFFICER | Buy | +1,402 | +$10.99K |
| 2023-11-02 | Robert J Michel | Chief Financial Officer | A | +2,000 | — |
| 2023-10-16 | Robert J Michel | Chief Financial Officer | Buy | +500 | +$4.51K |
| 2023-09-20 | of Joseph Feldschuh Estate | 10%+ Owner | G | −25,000 | — |
| 2023-07-13 | Henry D. Cremisi | Director | A | +2,500 deriv. | — |
| 2023-07-13 | Joy S. Goudie | Director | A | +2,500 deriv. | — |
| 2023-07-13 | Jonathan Adam Feldschuh | Chief Scientific Officer | A | +25,000 deriv. | — |
| 2023-07-13 | Michael Richard Feldschuh | Chairman, President & CEO | A | +30,000 deriv. | — |
| 2023-07-13 | Robert J Michel | Chief Financial Officer | A | +14,000 deriv. | — |
| 2023-07-13 | Edward Feuer | Director | A | +2,500 deriv. | — |
| 2023-07-13 | James A Lombard | Director | A | +2,500 deriv. | — |
| 2023-07-13 | Caleb DesRosiers | Director | A | +2,500 deriv. | — |
| 2023-05-25 | Joy S. Goudie | Director | Buy | +300 | +$2.92K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Michael Richard Feldschuh | Chief Executive Officer | 243,694 | $2.09M |
| Jonathan Adam Feldschuh | Chief Scientific Officer | 78,908 | $676.24K |
| Robert J Michel | Chief Financial Officer | 33,050 | $283.24K |
| John Jefferies | Chief Medical Officer | 26,008 | $222.89K |
| Caleb DesRosiers | Director | 3,157 | $27.06K |
| Edward Feuer | Director | 1,000 | $8.57K |
| Joy S. Goudie | Director | 300 | $2.57K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DXR quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.